Abstract
RationaleSelf-management is considered as an important part of disease management for people with pulmonary fibrosis (PF), but there is a lack of consensus regarding what components should be included. This study aimed to attain consensus from experts in PF and people living with the disease on the essential components and format of a PF self-management package.MethodsA two-round Delphi process was conducted. In each round, a panel of experts completed an online survey to rate a range of components, formats and delivery methods, followed by an online patient focus group to integrate patient perspectives. Consensus was defineda priori.Results45 experts participated in Round 1 and 51 in Round 2. Both focus groups included six people with PF. 12 components were considered essential for self-management in PF: 1) understanding treatment options; 2) understanding and accessing clinical trials; 3) managing medications; 4) role of oxygen therapy; 5) role and importance of pulmonary rehabilitation and regular physical activity; 6) managing shortness of breath; 7) managing fatigue; 8) managing mood; 9) managing comorbidities; 10) smoking cessation advice and support; 11) accessing community support; and 12) how to communicate with others when living with PF. Both groups agreed that self-management in PF required individualisation, goal setting and feedback.ConclusionThis study identified 12 essential components and highlighted individualisation, goal setting and feedback in self-management of PF. The findings provide a basis for the development of PF self-management interventions.
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference43 articles.
1. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
2. Fibrosing interstitial lung diseases: knowns and unknowns
3. Australian Government Department of Health Therapeutic Goods Administration . Australian public assessment report for pirfenidone. https://www.tga.gov.au/sites/default/files/auspar-pirfenidone-160809.pdf Date last updated: 9 August 2016. Date last accessed: 6 July 2022.
4. U.S. Food and Drug Administration . New drug therapy approvals 2020: advancing health through innovation. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2020 Date last updated: 1 August 2021. Date last accessed: 6 July 2022.
5. Australian Government Department of Health Therapeutic Goods Administration . Australian public assessment report for nintedanib (as Esilate). https://www.tga.gov.au/sites/default/files/auspar-nintedanib-as-esilate-210226.pdf Date last updated: 26 February 2021. Date last accessed: 6 July 2022.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献